{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:59:21Z","timestamp":1790881161277,"version":"4.1.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Both preclinical and retrospective studies have implicated \u03b2-adrenergic signaling in cancer progression, leading to interest in \u03b2-blockers (BBs) as adjunctive anticancer agents. There is evidence that they may enhance the sensitivity of cancer cells to radiotherapy and other conventional therapies. We conducted a systematic review and meta-analysis to explore the radiosensitizing effects of BBs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>PubMed, the Cochrane Library, Embase, Web of Science, the China National Knowledge Infrastructure, the China biology medicine database, Wan fang Data, and the VIP database were searched for articles in both English and Chinese from the establishment of the databases to September 8, 2025, to identify studies comparing outcomes according to beta-blocker use (yes vs no) in patients with solid tumors treated with radiotherapy. The primary endpoint was overall Survival (OS), Secondary objectives included 1, 2, 5-Year Survival, disease-free survival, distant metastasis-free survival, locoregional progression-free survival and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>8 studies (3165 patients), including 7 retrospective cohort studies and 1 randomized controlled trial, were analyzed. The most common cancer was non-small cell lung cancer (n\u2005=\u20055). BB use was associated with significantly improved OS (hazard ratio [HR] 0.73, 95% confidence interval: 0.64\u20130.83). Benefits were also observed for disease-free survival (HR 0.69) and Distant Metastasis-Free Survival (HR 0.62), indicating reduced recurrence and metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this meta-analysis, the use of BBs during or around radiotherapy may be associated with longer OS in cancer patients, suggesting that it may enhance the efficacy of radiotherapy and provide a survival benefit. Alternatively, the effect of \u03b2-blockers on survival may shift from a nonspecific effect to an intriguing cancer-specific effect over time. Beta-blockers are an intriguing option to explore in prospective studies of patients with solid tumors undergoing radiotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049582","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:01:12Z","timestamp":1784919672000},"page":"e49582","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Survival benefit of concurrent beta-blocker use in cancer patients treated with radiotherapy: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Wentong","family":"Xu","sequence":"first","affiliation":[{"name":"First Clinical College, Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"},{"name":"Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-2305","authenticated-orcid":false,"given":"Yong","family":"Xin","sequence":"additional","affiliation":[{"name":"First Clinical College, Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"},{"name":"Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[{"name":"First Clinical College, Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"},{"name":"Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Wu","sequence":"additional","affiliation":[{"name":"First Clinical College, Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"},{"name":"Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengchang","family":"Chen","sequence":"additional","affiliation":[{"name":"First Clinical College, Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"},{"name":"Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Lu","sequence":"additional","affiliation":[{"name":"Guangxi Medical University, Nanning, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Pizhou People\u2019s Hospital, Xuzhou, Jiangsu, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Pizhou People\u2019s Hospital, Xuzhou, Jiangsu, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1880-1352","authenticated-orcid":false,"given":"Fengjuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.radonc.2014.03.024","article-title":"Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012.","volume":"112","author":"Barton","year":"2014","journal-title":"Radiother Oncol"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JGO.2015.001545","article-title":"Global access to radiotherapy services: have we made progress during the past decade?","volume":"2","author":"Yap","year":"2016","journal-title":"J Global Oncol"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(00)00391-0","article-title":"Radiotherapy and cellular signalling.","volume":"2","author":"Lewanski","year":"2001","journal-title":"Lancet Oncol"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug\u2013radiotherapy combinations.","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s12276-021-00640-9","article-title":"Tumor microenvironment and radioresistance.","volume":"53","author":"Suwa","year":"2021","journal-title":"Exp Mol Med"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm0404-329a","article-title":"Recognition of tumor blood vessel normalization as a new antiangiogenic concept.","volume":"10","author":"Hellmann","year":"2004","journal-title":"Nat Med"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0360-3016(03)00511-X","article-title":"The epidermal growth factor receptor mediates radioresistance.","volume":"57","author":"Liang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"6 Pt B","key":"R9-20261001","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","article-title":"\u03b2-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy.","volume":"23","author":"Tang","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer.","volume":"18","author":"Cole","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases.","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"10702","DOI":"10.1038\/s41598-025-93205-z","article-title":"Beta-adrenergic receptor blockers improve survival in patients with advanced non-small cell lung cancer combined with hypertension undergoing radiotherapy.","volume":"15","author":"Liang","year":"2025","journal-title":"Sci Rep"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41586-023-06568-6","article-title":"The \u03b2(1)-adrenergic receptor links sympathetic nerves to T cell exhaustion.","volume":"622","author":"Globig","year":"2023","journal-title":"Nature"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-020-15676-0","article-title":"Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation.","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-08-2966","article-title":"Surgical stress promotes tumor growth in ovarian carcinoma.","volume":"15","author":"Lee","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/jcm8050575","article-title":"Effects of \u03b2-adrenergic antagonists on chemoradiation therapy for locally advanced non-small cell lung cancer.","volume":"8","author":"Chaudhary","year":"2019","journal-title":"J Clin Med"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mds616","article-title":"Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.","volume":"24","author":"Wang","year":"2013","journal-title":"Ann Oncol"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12094-016-1608-8","article-title":"Postdiagnostic use of \u03b2-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: an observational study of 10,414 person-years of follow-up.","volume":"19","author":"Kim","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.amjcard.2018.08.039","article-title":"Meta-analysis of carvedilol for the prevention of anthracycline-induced cardiotoxicity.","volume":"122","author":"Kheiri","year":"2018","journal-title":"Am J Cardiol"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","article-title":"Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy \u00b1 trastuzumab.","volume":"37","author":"Gujral","year":"2018","journal-title":"Breast"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"1957605","DOI":"10.1080\/2162402X.2021.1957605","article-title":"The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/jnci\/djaf056","article-title":"Antihypertensive drugs and survival outcomes in oropharyngeal squamous cell carcinoma patients.","volume":"117","author":"Lee","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/COC.0000000000000768","article-title":"Concurrent \u03b2-blocker use is associated with improved outcome in esophageal cancer patients who undergo chemoradiation: a retrospective matched-pair analysis.","volume":"43","author":"Farrugia","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"R27-20261001","article-title":"Effect of beta-blockers on survival rate of patients with non-small cell lung cancer after radiotherapy.","author":"Wang","year":"2016","journal-title":"Shaanxi Med J"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"S587","DOI":"10.1016\/j.ijrobp.2012.07.1566","article-title":"Improved survival outcomes in non-small cell lung cancer patients with incidental concurrent use of beta-blockers and definitive radiation therapy.","volume":"84","author":"Wang","year":"2012","journal-title":"Int J Radiation Oncol Biol Phys"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.12669\/pjms.38.5.5311","article-title":"Clinical value of propranolol combined with oxaliplatin and tigio in concurrent chemoradiotherapy for locally advanced gastric cancer.","volume":"38","author":"Chen","year":"2022","journal-title":"Pak J Med Sci"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/ph13060105","article-title":"Beta-blockers and cancer: where are we?","volume":"13","author":"Peixoto","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","article-title":"Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment.","volume":"41","author":"Fj\u00e6stad","year":"2022","journal-title":"Oncogene"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1517\/13543784.2013.825250","article-title":"\u03b2-blockers: a new role in cancer chemotherapy?","volume":"22","author":"Nagaraja","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"104587","DOI":"10.1016\/j.phrs.2019.104587","article-title":"\u03b2-blockers: their new life from hypertension to cancer and migraine.","volume":"151","author":"Fumagalli","year":"2020","journal-title":"Pharmacol Res"},{"key":"R34-20261001","doi-asserted-by":"crossref","first-page":"100066","DOI":"10.1016\/j.esmoop.2021.100066","article-title":"Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis.","volume":"6","author":"Caparica","year":"2021","journal-title":"ESMO Open"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2021.05.021","article-title":"Cardiovascular medications and survival in people with ovarian cancer: a population-based cohort study from British Columbia, Canada.","volume":"162","author":"Hanley","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2013.01.007","article-title":"Association between use of \u03b2-blockers and prostate cancer\u2013specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.","volume":"65","author":"Grytli","year":"2014","journal-title":"Eur Urol"},{"key":"R37-20261001","doi-asserted-by":"crossref","first-page":"104149","DOI":"10.1016\/j.ebiom.2022.104149","article-title":"Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma.","volume":"82","author":"Rossi","year":"2022","journal-title":"EBioMedicine"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2147\/DDDT.S160865","article-title":"The role of propranolol as a radiosensitizer in gastric cancer treatment.","volume":"12","author":"Liao","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1667\/RR15193.1","article-title":"Adrenergic receptor signaling regulates the response of tumors to ionizing radiation.","volume":"191","author":"MacDonald","year":"2019","journal-title":"Radiat Res"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41389-018-0090-2","article-title":"\u03b22-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent\/metastatic HPV (+) HNSCC.","volume":"7","author":"Lucido","year":"2018","journal-title":"Oncogenesis"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","article-title":"Beta blockers and breast cancer mortality: a population- based study.","volume":"29","author":"Barron","year":"2011","journal-title":"J Clin Oncol"},{"key":"R42-20261001","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","article-title":"Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.","volume":"29","author":"Melhem-Bertrandt","year":"2011","journal-title":"J Clin Oncol"},{"key":"R43-20261001","doi-asserted-by":"crossref","first-page":"628","DOI":"10.18632\/oncotarget.197","article-title":"Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.","volume":"1","author":"Powe","year":"2010","journal-title":"Oncotarget"},{"key":"R44-20261001","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1476-4598-10-146","article-title":"\u03b22-adrenoceptor blockage induces G1\/S phase arrest and apoptosis in pancreatic cancer cells via Ras\/Akt\/NF\u03baB pathway.","volume":"10","author":"Zhang","year":"2011","journal-title":"Mol Cancer"},{"key":"R45-20261001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/jid.2014.373","article-title":"Inhibition of human melanoma growth by a non-cardioselective \u03b2-blocker.","volume":"135","author":"Wrobel","year":"2015","journal-title":"J Invest Dermatol"},{"key":"R46-20261001","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMcibr1714003","article-title":"Innervating prostate cancer.","volume":"378","author":"Chen","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:01:33Z","timestamp":1790877693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":46,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049582","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"2025-11-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}